Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. (1st June 2020)

• Record Type: Journal Article
• Authors: Berlow, Noah E.; Grasso, Catherine S.; Quist, Michael J.; Cheng, Mingshan; Gandour-Edwards, Regina; Hernandez, Brian S.; Michalek, Joel E.; Ryan, Christopher; Spellman, Paul; Pal, Ranadip; Million, Lynn S.; Renneker, Mark; Keller, Charles
• Other Names: Verhoef Cornelis Academic Editor.
• Is Part Of: Sarcoma. Volume 2020(2020)
• Publication Date: 2020-06-01
• Subjects: Sarcoma -- Periodicals; 616.994
• DOI: 10.1155/2020/6312480
• Languages: English
• ISSNs: 1357-714X

Abstract

Abstract : Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a class of 50+ cancers arising in muscle and soft tissues of children, adolescents, and adults. Rarity of each subtype often precludes subtype-specific preclinical research, leaving many STS patients with limited treatment options should frontline therapy be insufficient. When clinical options are exhausted, personalized therapy assignment approaches may help direct patient care. Here, we report the results of an adult female STS patient with relapsed undifferentiated pleomorphic sarcoma (UPS) who self-drove exploration of a wide array of personalized Clinical Laboratory Improvement Amendments (CLIAs) level and research-level diagnostics, including state of the art genomic, proteomic, ex vivo live cell chemosensitivity testing, a patient-derived xenograft model, and immunoscoring. Her therapeutic choices were also diverse, including neoadjuvant chemotherapy, radiation therapy, and surgeries. Adjuvant and recurrence strategies included off-label and natural medicines, several immunotherapies, and N-of-1 approaches. Identified treatment options, especially those validated during the in vivo study, were not introduced into the course of clinical treatment but did provide plausible treatment regimens based on FDA-approved clinical agents.